Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect.

已完结 10 由小钱发布于 2025/2/10 17:06:47

DOI:10.1158/1535-7163.MCT-20-0166
作者：Aleksandr V Yurkovetskiy,?Natalya D Bodyak,?Mao Yin,?Joshua D Thomas,?Susan M Clardy,?Patrick R Conlon,?Cheri A Stevenson,?Alex Uttard,?LiuLiang Qin,?Dmitry R Gumerov,?Elena Ter-Ovanesyan,?Charlie Bu,
文献类型：期刊论文
补充材料：只需要正文

American Association for Cancer Research (AACR)

Abstract：After significant effort over the last 30 years, antibody-drug conjugates (ADC) have recently gained momentum as a therapeutic modality, and nine ADCs have been approved by the FDA to date,

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierEffect of alkali doping on alkaline stability and cell performance of quaternization polyvinyl alcohol/graphene oxide membranes for passive DEFCs